INDIRECT ACCESS PROGRAM

If your facility/pharmacy is approved for an indirect access, via Letter of Agreement (LOA) or Restricted Access Certification (RAC)

• A non-negotiable LOA will be forwarded to the email provided in the online application via Docusign for signature
• Once countersigned your facility will be forwarded an electronic copy of the executed agreement
  • Agreements are generally for 2-year terms
• The Approved Purchasers List (APL) is updated by Contract Operations for the Product(s) on the executed agreement and forwarded to our authorized distributors. Please reach out to [email protected] if you need a detail of those authorized distributors.
• Once our distributors receive that APL including your facility/pharmacy, you may begin purchasing product
  • It can take up to 24 hours for distributors to update their systems

DATA REPORTING ONBOARDING

After executing an LOA our Data Reporting team will reach out with an orientation on the different sales reporting mechanisms and how to manage the data reporting requirements of your agreement.

Data Reporting can be fulfilled in one of two ways:

• Our Genentech Sales Tracker: Online portal for lower volume pharmacies with limited data reporting resources
• Flat file submission of data elements in Exhibit C of your agreement

CONTRACT EXECUTION TIMELINE FOR APPROVED FACILITIES

Once approved, and if the Contract Operations team receives a timely return of the signed LOA, the process to gain pharmacy or infusion site product access can be as soon as 4-5 business days. Lapses in communication or incomplete submissions can add unforeseeable time to the execution of an indirect access LOA.

In some cases, we are unable to extend indirect access to a facility for a number of reasons, including but not exclusively when the existing distribution network is considered sufficient for meeting patient access. If your request is denied, you may pursue a Patient Specific exception or learn other options by contacting Genentech Access Solutions.

A Patient Specific Exception may be approved if one of the criteria below apply:

• If your facility/pharmacy has a Payor or Employer Mandate.
  A Payor or Employer Mandate is contractual obligation that stipulates that only your pharmacy and no other pharmacy can fill the prescription for the product in question.
• If the network for product access is not accepting new facilities/pharmacies and there is a patient waiting with a prescription in hand.
• For ACTEMRA^® (tocilizumab), OCREVUS^® (ocrelizumab), and applicable BioOncology products the Prescriber or Patient expresses a facility/pharmacy preference.

If your facility is not eligible for indirect access and any of the above apply please contact our Access Solutions team at (866) 422‑2377 regarding Patient Specific Exception eligibility.